Prognostic Factors in Glioblastoma Multiforme 10 Years Experience of a Single Institution

Hulshof, Maarten C.C.M.; Koot, Radboud W.; Schimmel, Erik C.; Dekker, Friedo W.; Bosch, Dirk; González, Dionisio González

doi:10.1007/pl00002409

Cited by 61 publications

(50 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(1,11,20) These factors include age, performance status, histology, extent of surgical resection, and the addition of radiotherapy and chemotherapy as adjuvants. Some authors have attempted to stratify patients into prognostic groups based on these factors in order to predict survival.…”

Section: Discussionmentioning

confidence: 99%

Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions

Cheo¹,

Lim²,

Lim³

2017

smedj

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions

Cheo¹,

Lim²,

Lim³

2017

smedj

View full text Add to dashboard Cite

“…For many years, surgical resection followed by radiation therapy has been the standard treatment for gliomas, resulting in a median survival of less than 1 year after initial diagnosis [1][2][3]. Since the study of Stupp et al [4], showing a significant prolongation of survival by additional administration of temozolomide, the new standard of care for glioblastoma multiforme now consists of surgery, radiotherapy and temozolomide [4].…”

Section: Introductionmentioning

confidence: 99%

Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells

et al. 2007

View full text Add to dashboard Cite

The COX-2 protein is frequently overexpressed in human malignant gliomas. This expression has been associated with their aggressive growth characteristics and poor prognosis for patients. Targeting the COX-2 pathway might improve glioma therapy. In this study, the effects of the selective COX-2 inhibitor meloxicam alone and in combination with irradiation were investigated on human glioma cells in vitro. A panel of three glioma cell lines (D384, U87 and U251) was used in the experiments from which U87 cells expressed constitutive COX-2. The response to meloxicam and irradiation (dose-range of 0-6 Gy) was determined by the clonogenic assay, cell proliferation was evaluated by growth analysis and cell cycle distribution by FACS. 24-72 h exposure to 250-750 lM meloxicam resulted in a time and dose dependent growth inhibition with an almost complete inhibition after 24 h for all cell lines. Exposure to 750 lM meloxicam for 24 h increased the fraction of cells in the radiosensitive G 2 /M cell cycle phase in D384 (18-27%) and U251 (17-41%) cells. 750 lM meloxicam resulted in radiosensitization of D384 (DMF:2.19) and U87 (DMF:1.25) cells, but not U251 cells (DMF:1.08). The selective COX-2 inhibitor meloxicam exerted COX-2 independent growth inhibition and radiosensitization of human glioma cells.

show abstract

“…The resection group in our study combined both groups of patients who underwent partial and total resection. 21 Nonetheless, the significance of this factor for predicting survival was very high. RT with concomitant temozolomide showed a significant improvement in survival as shown in the literature.…”

Section: Discussionmentioning

confidence: 99%

The Potential Impact of Delayed Radiation Therapy on Patients with Glioblastoma

Alnaami

VanderPluym

Murtha

et al. 2013

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

790Glioblastoma is the most prevalent and aggressive primary malignant brain tumor in adults.1 Since the publication of Stupp et al., the standard of care for the treatment of glioblastoma includes maximal surgical resection followed by radiation therapy (RT) and concomitant and adjuvant temozolomide treatment. Despite the use of this state-of-the-art treatment regimen, the median survival time of patients with glioblastoma is only 14.6 months.1 Well-established favorable prognostic factors include the addition of RT and novel chemotherapeutic agents such as temozolomide, the maximal extent of surgical resection, younger age, and a higher Karnofsky Performance Score 2-5 . The addition of RT to treatment protocols in three randomized phase III trials demonstrated an approximate doubling of survival and has been the considered standard of care since the late 1970's. [6][7][8] The standard time for RT for most patients is between two and six weeks following surgery 6,9-12 ; however, in certain resource-limited centers, it may be as long as ABSTRACT: Background: Radiation therapy (RT) is the major component of glioblastoma treatment; however, the time to initiate RT after surgical intervention varies between institutions. Our study examined the time from diagnosis to the initiation of RT and its effects on overall patient survival. Methods: We retrospectively examined 267 patients with glioblastoma who received RT as part of their therapy in two Canadian tertiary care centers. The primary goal of the study is to assess if time to RT can predict/impact survival in glioblastoma patients. Results: The following variables were associated with an increased risk of death: hazard ratio (HR) of time to RT was 0.95 [95% confidence interval (CI), 0.91-0.99] for every extra week. HRs for the type of surgery (resection or biopsy) and type of management received (standard of care in comparison with RT regardless of chemotherapeutic agents other than concomitant and adjuvant temozolomide) were 0.50 (95% CI, 0.37-0.66) and 0.53 (95% CI, 0.38-0.75), respectively. HR for age was 1.02 (95% CI, 1.01-1.03) for every extra year. Standard 60 Gy RT HR was 0.70 [95% confidence interval (CI), 0.51-0.97] in younger patients. Conclusions:The time from diagnosis to the initiation of RT was found to be a significant prognostic factor for overall patient survival. The addition of temozolomide to the treatment protocol, age, standard RT dose in younger patients and extent of surgery are others factors associated with longer survival periods.RÉSUMÉ: Impact potentiel de la radiothérapie différée chez les patients atteints d'un glioblastome. Contexte : la radiothérapie (RT) est l'élément le plus important du traitement du glioblastome. Cependant, le moment du début de la RT après la chirurgie varie selon les institutions. le but de l'étude était d'examiner le temps écoulé à partir du moment où le diagnostic a été posé jusqu'au moment où la RT a été commencée et ses effets sur la survie globale des patients. Méthode : Nous avons examiné rétrospective...

show abstract

Prognostic Factors in Glioblastoma Multiforme 10 Years Experience of a Single Institution

Cited by 61 publications

References 24 publications

Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions

Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions

Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells

The Potential Impact of Delayed Radiation Therapy on Patients with Glioblastoma

Contact Info

Product

Resources

About